REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)

6 Months Ended

Jun. 30, 2019

Concentration Risk And Geographic Information [Abstract]

Schedule of Total Revenues from External Customers and Collaborative Partners by Geographic Region

The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme. Although Sanofi Genzyme (Genzyme) sells Aldurazyme worldwide, the revenues earned by the Company are included in the U.S. region, as the transactions are with Genzyme whose headquarters is located in the U.S. Genzyme is the Company’s sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties. 

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Total revenues by geographic region:
United States	$	169,407	$	162,789	$	360,343	$	353,360
Europe	119,561		107,221		244,100		212,871
Latin America	46,494		38,152		80,333		76,555
Rest of world	52,301		64,683		103,732		103,506
Total revenues	$	387,763	$	372,845	$	788,508	$	746,292

Schedule of Net Product Revenues by Product

The following table disaggregates Net Product Revenues by product. 

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Net product revenues by product:
Aldurazyme	$	5,826	$	24,003	$	51,093	$	90,059
Brineura	14,795		10,890		26,975		17,807
Firdapse	5,482		5,177		10,594		10,103
Kuvan	113,323		109,045		220,247		208,160
Naglazyme	98,127		91,086		185,054		166,082
Palynziq	18,836		—		31,108		—
Vimizim	122,686		127,585		248,487		244,674
Total net product revenues	$	379,075	$	367,786	$	773,558	$	736,885

Schedule of Total Net Product Revenues Based on Patient Location

The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme, the Company’s sole customer for Aldurazyme. 

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
United States	$	160,918	$	138,411	$	305,203	$	262,552
Europe	113,593		102,621		236,678		207,419
Latin America	46,493		48,844		80,333		76,555
Rest of world	52,245		53,907		100,251		100,300
Total net product revenues marketed by the Company	373,249		343,783		722,465		646,826
Aldurazyme net product revenues marketed by Genzyme	5,826		24,003		51,093		90,059
Total net product revenues	$	379,075	$	367,786	$	773,558	$	736,885

Schedule of Net Product Revenue Concentrations Attributed to Largest Customers

The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. 

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Customer A	16	%	18	%	17	%	18	%
Customer B	13	%	12	%	12	%	12	%
Customer C	12	%	10	%	11	%	9	%
Customer D	2	%	7	%	7	%	12	%
Total	43	%	47	%	47	%	51	%